ADNT
Adient plc
ADNT has the edge over TSLA overall, supported by stronger valuation and stronger fundamentals.
TSLA
Tesla, Inc.
TSLA's outlook is improving, though it still trails on the overall score.
ADNT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Stable |
ADNT's revenue, profitability, cash flow and balance sheet are all currently stable.
TSLA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
TSLA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
ADNT PE Valuation
ADNT has no meaningful PE right now: it lost money over the past year.
TSLA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 60x | $54.70 | -86% |
| Fair | 174x | $158 | -60% |
| Forward | 196x | $397 | — |
| Expensive | 415x | $378 | -4.9% |
| Current | 437x | $397 | — |
Historical ranges are pointers, not guarantees.
TSLA's PE is in its expensive range at 437x. If earnings grow as analysts expect, today's price would be 196x next year's earnings, in its fair range.
ADNT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect ADNT's earnings to grow, with its revenue and profitability holding steady. However, they disagree widely on these estimates.
TSLA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
TSLA has the edge over ADNT on the outlook, with more favorable revenue expectations.
ADNT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.69 | — |
| Q3 2026 | -$0.24 | +$3.15 |
ADNT lost $0.24 per share over the past year, a smaller loss than the year before.
TSLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.03 | +123% |
| Q3 2026 | $0.91 | -39% |
| Q2 2026 | $1.08 | -38% |
| Q1 2026 | $1.09 | -40% |
| Q4 2025 | $1.08 | -47% |
| Q3 2025 | $1.50 | -59% |
| Q2 2025 | $1.73 | -51% |
| Q1 2025 | $1.82 | -53% |
| Q4 2024 | $2.04 | -53% |
TSLA has the edge over ADNT in the latest year-over-year earnings comparison.
ADNT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +1.1% |
| Q2 2026 | $3.9B | +5% |
| Q1 2026 | $3.9B | +7% |
| Q4 2025 | $3.6B | +4.3% |
ADNT's revenue has grown year over year every quarter since late 2025: $3.7B last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 1.6% | -0.1 points |
| Q1 2026 | 2% | +9.3 points |
| Q4 2025 | 1.1% | -0.2 points |
| Q3 2025 | 1.7% | N/A |
| Q2 2025 | 1.8% | N/A |
| Q1 2025 | -7.3% | N/A |
| Q4 2024 | 1.3% | N/A |
ADNT's operating margin was 1.6% last quarter, about level with the same quarter a year ago.
TSLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $28B | -0.2% |
| Q2 2026 | $28.2B | +26% |
| Q1 2026 | $22.4B | +16% |
| Q4 2025 | $24.9B | -3.1% |
| Q3 2025 | $28.1B | +12% |
| Q2 2025 | $22.5B | -12% |
| Q1 2025 | $19.3B | -9.2% |
| Q4 2024 | $25.7B | +2.1% |
TSLA's revenue has picked up after two years of holding roughly level: $28B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.6% | -3.2 points |
| Q2 2026 | 1.4% | -2.7 points |
| Q1 2026 | 4.2% | +2.1 points |
| Q4 2025 | 5.7% | -0.5 points |
| Q3 2025 | 5.8% | -5 points |
| Q2 2025 | 4.1% | -2.2 points |
| Q1 2025 | 2.1% | -3.4 points |
| Q4 2024 | 6.2% | -2 points |
TSLA has the edge over ADNT on profitability, with a higher operating margin.
ADNT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $138M | +20% |
| Q1 2026 | $8M | +$98M |
| Q4 2025 | $15M | -67% |
ADNT has the edge over TSLA in the latest year-over-year cash flow comparison.
TSLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | -62% |
| Q2 2026 | -$1.1B | -848% |
| Q1 2026 | $1.4B | +117% |
| Q4 2025 | $1.4B | -30% |
| Q3 2025 | $4B | +46% |
| Q2 2025 | $146M | -89% |
| Q1 2025 | $664M | +$3.2B |
| Q4 2024 | $2B | -1.6% |
TSLA still generates free cash flow, though less than at its 2025 peak: $3.3B over the past year.
ADNT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -100K shares |
| 1 year | -5.4% | -4.5M shares |
ADNT has the edge over TSLA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $30M |
| Q1 2026 | — |
| Q4 2025 | $25M |
| Q3 2025 | $50M |
| Q2 2025 | $50M |
| Q1 2025 | — |
| Q4 2024 | $25M |
ADNT spent $105M buying back its own shares over the past year.
TSLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1M shares |
| 1 year | +0.4% | +15M shares |
| 3 years | +1.4% | +48M shares |
| 5 years | +5.1% | +172M shares |
| Available history | +33% | +886M shares |
TSLA has 3.5B diluted shares, about the same as a year ago.
ADNT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 2.6x | Moderate |
| Q1 2026 | 2.7x | Moderate |
| Q4 2025 | 6.7x | High |
| Q3 2025 | 6.1x | High |
| Q2 2025 | 6.5x | High |
| Q1 2025 | 7.6x | High |
| Q4 2024 | 3.5x | Elevated |
ADNT's net debt is about 2.5 years of its operating earnings (EBITDA), down from 6.5 years a year ago.
TSLA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -0.9x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.1x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
TSLA has the edge over ADNT on leverage, with a lower net debt burden relative to earnings.
ADNT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.6 | Neutral |
| Stochastic | 8.3 | Oversold |
ADNT's weekly RSI is 35 (neutral) and its Stochastic is 8 (oversold).
TSLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 72.6 | Neutral |
TSLA's weekly RSI is 54 (neutral) and its Stochastic is 73 (neutral).
ADNT PE vs Consumer Cyclical Sector
| Metric | ADNT | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 18x | 68% above |
| PE % | 59 | 47 | 12 pts above |
ADNT has the edge over TSLA on valuation relative to its sector.
TSLA PE vs Consumer Cyclical Sector
| Metric | TSLA | Sector median | Relative |
|---|---|---|---|
| PE | 437x | 18x | 2,324% above |
| PE % | 84 | 47 | 37 pts above |
TSLA is trading at 437x earnings, a 2324% premium to the Consumer Cyclical sector's median of 18x.
ADNT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.0 | 6.8% below |
| 20 week MA | $18.6 | 15% below |
| 50 week MA | $20.3 | 22% below |
| 100 week MA | $19.5 | 19% below |
| 200 week MA | $25.9 | 39% below |
ADNT is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
TSLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $376.0 | 5.7% above |
| 20 week MA | $364.0 | 9.2% above |
| 50 week MA | $393.6 | 1% above |
| 100 week MA | $372.1 | 6.8% above |
| 200 week MA | $296.9 | 34% above |
TSLA has the edge over ADNT on trend strength, trading above more of its moving averages.
ADNT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.3 | $34.6 | +63% |
| 2021 | $34.6 | $46.9 | +36% |
| 2022 | $46.9 | $34.1 | -27% |
| 2023 | $34.1 | $36.4 | +6.8% |
| 2024 | $36.4 | $17.4 | -52% |
| 2025 | $17.4 | $19.5 | +12% |
| 2026 YTD | $19.5 | $15.8 | -19% |
ADNT has finished higher in four of the last six years. It's down 19% so far in 2026.
TSLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.7 | $220.6 | +669% |
| 2021 | $220.6 | $355.7 | +61% |
| 2022 | $355.7 | $123.2 | -65% |
| 2023 | $123.2 | $248.5 | +102% |
| 2024 | $248.5 | $431.7 | +74% |
| 2025 | $431.7 | $475.2 | +10% |
| 2026 YTD | $475.2 | $397.5 | -16% |
TSLA has the edge over ADNT on returns for 2026, with the stronger performance.